Se requiere una suscripción a JoVE para ver este contenido. Inicie sesión o comience su prueba gratuita.
This study presents an orthotopic non-small cell lung cancer (NSCLC) model based on intrapulmonary inoculation of multicellular spheroids of fluorescent A549-iRFP cells. The model recapitulates clinical NSCLC stages and responds to cisplatin, according to dynamic in vivo monitoring of long-wavelength fluorescence.
Non-small cell lung cancer (NSCLC) is a highly lethal disease with a complex and heterogeneous tumor microenvironment. Currently, common animal models based on subcutaneous inoculation of cancer cell suspensions do not recapitulate the tumor microenvironment in NSCLC. Herein we describe a murine orthotopic lung cancer xenograft model that employs the intrapulmonary inoculation of three-dimensional multicellular spheroids (MCS). Specifically, fluorescent human NSCLC cells (A549-iRFP) were cultured in low-attachment 96-well microplates with collagen for 3 weeks to form MCS, which were then inoculated intercostally into the left lung of athymic nude mice to establish the orthotopic lung cancer model.
Compared with the original A549 cell line, MCS of the A549-iRFP cell line responded similarly to anticancer drugs. The long-wavelength fluorescent signal of the A549-iRFP cells correlated strongly with common markers of cancer cell growth, including spheroid volume, cell viability, and cellular protein level, thus allowing dynamic monitoring of the cancer growth in vivo by fluorescent imaging. After inoculation into mice, the A549-iRFP MCS xenograft reliably progressed through phases closely resembling the clinical stages of NSCLC, including the expansion of the primary tumor, the emergence of neighboring secondary tumors, and the metastases of cancer cells to the contralateral right lung and remote organs. Moreover, the model responded to the benchmark antilung cancer drug, cisplatin with the anticipated toxicity and slower cancer progression. Therefore, this murine orthotopic xenograft model of NSCLC would serve as a platform to recapitulate the disease's progression and facilitate the development of potential anticancer drugs.
Among all oncological disorders, lung cancer not only inflicts the highest life loss but also claims the second-highest number of new patients every year in the US1. This devastating malignancy stands as a major obstacle in modern healthcare, urging for a deeper understanding of its intricate biology and more efficacious therapeutic modalities2. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer and tends to develop into solid tumors3. One of the foremost challenges in lung cancer is the dynamic and heterogeneous tumor microenvironment, which profoundly influences the cancer's ....
The animal study was performed with the approval of the Institutional Animal Care and Use Committee (IACUC) at the University of the Pacific (Animal Protocols 19R10 and 22R10). Eight Male athymic nude mice aged 5-6 weeks, weighing 20-25 g, bred with the referenced Rodent Diet and housed under pathogen-free (SPF) conditions, were used for the present study. Cages, bedding, and drinking water were autoclaved and changed regularly. A schematic of tumor inoculation in mice is shown in Figure 1. .......
Characterization of A549-iRFP MCS
A549-iRFP MCS were successfully cultured in spheroid microplates with the assistance of collagen and centrifugation. When MCS reached a diameter of approximately 500 µm after 1 week, both A549 and A549-iRFP MCS were exposed to a variety of anticancer drugs and formulations for 3 days and then maintained in drug-free growth medium for 4 additional days. The A549-iRFP MCS exhibited a response pattern closely mirroring that of the parent A549 cells. A549 and A549.......
The construction of A549-iRFP MCS is a straightforward and highly reproducible lab procedure and can be translated to MCS formation for multiple cell lines. The MCS generated with the aid of centrifugation and collagen exhibits a more integral and solid-tumor-like structure within 3-4 days. This method ensures the formation of robust spheroids that maintain their integral structure for extended periods, typically 2-3 weeks or even longer until small buddings begin to emerge. By employing centrifugation and collagen, we s.......
This work was supported by SAAG and SEED grants from the University of the Pacific. We thank Dr. William Chan for granting access to the Odyssey Infrared Imaging 205 System and Dr. John Livesey for granting access to the SpectraMax iD3 plate reader. We thank Dr. Melanie Felmlee for the technical advice on the animal protocols.
....Name | Company | Catalog Number | Comments |
100 µL Glass Syringe | Hamilton | Part/REF #80601 | |
20 G Needle | Thermo Fisher Scientific Inc. | 14 826D | |
96-well Ultra-Low-Attachment Spheroid Microplate | Corning | 15-100-173 | |
A549-iRFP | Imanis Life Sciences | CL082-STAN | |
AIN-93M Mature Rodent Diet | Research Diets, Inc. | D10012M | |
Athymic Nude Mouse | Charles River Laboratories, Inc. | Strain Code: 490; homozygous | |
BCA | Pierce | 23227 | |
Buprenorphine Hydrochloride | Patterson Veterinary | NDC Number: 42023-179-05 | |
CellTiter-Glo 3D Cell Viability Assay | Promega | G9683 | |
Collagen | Gibco | A1064401 | |
DMEM | Corning | MT10013CV | |
Fetal Bovine Serum (FBS) | Cytiva HyClone | SH3039603 | |
ImageJ | Open source tool (https://imagej.net/ij/) | N/A | |
Image Studio | LI-COR | Version 5.2 | |
Isoflurane | Patterson Veterinary | NDC Number: 17033-0091-25 | |
Ketamine | Patterson Veterinary | NDC Number: 50989-0161-06 | |
Microscope | Keyence | Model number: BZ-X710 | |
Matrigel | Corning | CB-40234 | |
Odyssey Infrared Imaging 205 System | LI-COR | Model number: 9140 | |
PBS | Corning | MT21040CV | |
Pearl Trilogy small animal imaging system | LI-COR | Model number: 9430 | |
Penicillin-Streptomycin | Corning | MT30002CI | |
Puromycin | Thermo Fisher Scientific Inc. | AAJ67236XF | |
ReViSP software from MATLAB | Open source tool on Sourceforge (https://sourceforge.net/projects/revisp/) | N/A | |
Surgical Clips--AutoClip System | Fine Science Tools | 12020-00 | |
Xylazine | Patterson Veterinary | NDC Number: 61133-6017-01 |
This article has been published
Video Coming Soon
ACERCA DE JoVE
Copyright © 2025 MyJoVE Corporation. Todos los derechos reservados